Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1D | P48730 | 10/20 | 0.58 |
| ▸ | CSNK1E | P49674 | 10/20 | 0.58 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.52 |
| ▸ | KDR | P35968 | 8/20 | 0.51 |
| ▸ | ABL1 | P00519 | 2/20 | 0.50 |
| ▸ | CSF1R | P07333 | 1/20 | 0.49 |
| ▸ | YES1 | P07947 | 1/20 | 0.49 |
| ▸ | RET | P07949 | 1/20 | 0.49 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.49 |
| ▸ | BCR | P11274 | 1/20 | 0.49 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.49 |
| ▸ | FLT1 | P17948 | 1/20 | 0.49 |
| ▸ | FLT4 | P35916 | 1/20 | 0.49 |
| ▸ | ABL2 | P42684 | 1/20 | 0.49 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.49 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.49 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.49 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 0.49 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.49 |
| ▸ | BMP2K | Q9NSY1 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23795715 | 0.89 | CSNK1D (0.56) | CSNK1DCSNK1EKDRABL1CSF1R | |
| SCHEMBL23795721 | 0.87 | CSNK1D (0.54) | CSNK1DCSNK1EKDRABL1CSF1R | |
| SCHEMBL25540639 | 0.85 | CSNK1D (0.52) | CSNK1DCSNK1EKDRABL1CSF1R | |
| SCHEMBL25540594 | 0.80 | LRRK2 (0.77) | LRRK2ABL1 | |
| SCHEMBL23761188 | 0.76 | KDR (0.54) | CSNK1DCSNK1EKDRABL1CSF1R | |
| SCHEMBL13756343 | 0.75 | KDR (0.57) | CSNK1DCSNK1ELRRK2KDRMET | |
| SCHEMBL12225956 | 0.74 | KDR (0.71) | KDRABL1CSF1RYES1RET | |
| SCHEMBL248352 | 0.74 | KDR (0.56) | CSNK1DCSNK1EKDRMET | |
| SCHEMBL3397547 | 0.74 | KDR (0.56) | CSNK1DCSNK1EKDRPDGFRBFLT1 | |
| SCHEMBL245728 | 0.74 | KDR (0.56) | CSNK1DCSNK1EKDRABL1CSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230151001-A9 | IMIDAZOPYRIDINE DERIVATIVES AND AZA-IMIDAZOPYRIDINE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151001-A9 | IMIDAZOPYRIDINE DERIVATIVES AND AZA-IMIDAZOPYRIDINE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF | JAK1, JAK2, JAK3 | CSNK1D 20/4885CSNK1E 87/4885LRRK2 2176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.